Keytruda Increases Survival of Lung Cancer Patients, Compared with Standard Chemo, Update Shows
lung cancer, News
Keytruda (pembrolizumab) reduced the risk of non-small cell lung cancer patients dying by 37 percent, compared with standard chemotherapy, according to updated information from a Phase 3 clinical trial. Sixty-one percent ... Read more